Antibody profiles in COVID-19 convalescent plasma prepared with amotosalen/UVA pathogen reduction treatment.

Autor: Bagri A; Transfusion Medicine Research, Cerus Corporation, Concord, California, USA., de Assis RR; Department of Physiology and Biophysics, School of Medicine, University of California Irvine, Irvine, California, USA., Tsai CT; Enable Biosciences Inc, South San Francisco, California, USA., Simmons G; Scientific Research Programs, Vitalant Research Institute, San Francisco, California, USA., Mei ZW; Wing-Kwai and Alice Lee-Tsing Chung Transfusion Service, Department of Pathology and Laboratory Medicine, David Geffen School of Medicine at University of California, Los Angeles, California, USA., Von Goetz M; Transfusion Medicine Research, Cerus Corporation, Concord, California, USA., Gatmaitan M; Transfusion Medicine Research, Cerus Corporation, Concord, California, USA., Stone M; Scientific Research Programs, Vitalant Research Institute, San Francisco, California, USA., Di Germanio C; Scientific Research Programs, Vitalant Research Institute, San Francisco, California, USA., Martinelli R; Scientific Research Programs, Vitalant Research Institute, San Francisco, California, USA., Darst O; Scientific Research Programs, Vitalant Research Institute, San Francisco, California, USA., Rioveros J; Wing-Kwai and Alice Lee-Tsing Chung Transfusion Service, Department of Pathology and Laboratory Medicine, David Geffen School of Medicine at University of California, Los Angeles, California, USA., Robinson PV; Enable Biosciences Inc, South San Francisco, California, USA., Ward D; Wing-Kwai and Alice Lee-Tsing Chung Transfusion Service, Department of Pathology and Laboratory Medicine, David Geffen School of Medicine at University of California, Los Angeles, California, USA., Ziman A; Wing-Kwai and Alice Lee-Tsing Chung Transfusion Service, Department of Pathology and Laboratory Medicine, David Geffen School of Medicine at University of California, Los Angeles, California, USA., Seftel D; Enable Biosciences Inc, South San Francisco, California, USA., Khan S; Division of Infectious Diseases, Department of Medicine, University of California Irvine Health, Orange, California, USA., Busch MP; Scientific Research Programs, Vitalant Research Institute, San Francisco, California, USA., Felgner PL; Department of Physiology and Biophysics, School of Medicine, University of California Irvine, Irvine, California, USA., Corash LM; Transfusion Medicine Research, Cerus Corporation, Concord, California, USA.
Jazyk: angličtina
Zdroj: Transfusion [Transfusion] 2022 Mar; Vol. 62 (3), pp. 570-583. Date of Electronic Publication: 2022 Feb 12.
DOI: 10.1111/trf.16819
Abstrakt: Background: COVID-19 convalescent plasma (CCP), from donors recovered from severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection, is one of the limited therapeutic options currently available for the treatment of critically ill patients with COVID-19. There is growing evidence that CCP may reduce viral loads and disease severity; and reduce mortality. However, concerns about the risk of transfusion-transmitted infections (TTI) and other complications associated with transfusion of plasma, remain. Amotosalen/UVA pathogen reduction treatment (A/UVA-PRT) of plasma offers a mitigation of TTI risk, and when combined with pooling has the potential to increase the diversity of the polyclonal SARS-CoV-2 neutralizing antibodies.
Study Design and Methods: This study assessed the impact of A/UVA-PRT on SARS-CoV-2 antibodies in 42 CCP using multiple complimentary assays including antigen binding, neutralizing, and epitope microarrays. Other mediators of CCP efficacy were also assessed.
Results: A/UVA-PRT did not negatively impact antibodies to SARS-CoV-2 and other viral epitopes, had no impact on neutralizing activity or other potential mediators of CCP efficacy. Finally, immune cross-reactivity with other coronavirus antigens was observed raising the potential for neutralizing activity against other emergent coronaviruses.
Conclusion: The findings of this study support the selection of effective CCP combined with the use of A/UVA-PRT in the production of CCP for patients with COVID-19.
(© 2022 The Authors. Transfusion published by Wiley Periodicals LLC on behalf of AABB.)
Databáze: MEDLINE
Externí odkaz: